Xuebijing Injection in the Treatment of Severe Pneumonia: A Randomized Controlled Trial

Protocol Amendments
March 18, 2016

Trial Registration: Chinese Clinical Trials Registry ChiCTR-TRC-13003534.

Prepared for and approved by the Executive committee of the study:

Dr. Chunxue Bai, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai Institute of Respiratory Medicine, Shanghai 200032, China.

Dr. Hongcai Shang, Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Haiyuncang Lane, Dongcheng District, Beijing 100700, China.
1. Page 5, Randomization section, The published protocol mistakenly mentioned the source of infection include community- or hospital-acquired infection, whereas the original protocol did not include patients admitted to the hospital for more than 48 hours.

2. Page 3, Table 1 Research settings and name of each ethics committee, three settings were missed.
   (1) Luoyang Central Hospital Affiliated to Zhengzhou University
   (2) First People’s Hospital of Yunnan Province
   (3) Central Hospital Affiliated to Shenyang Medical College

3. Page 6, Secondary outcome measures, PSI score, Sequential Organ Failure Assessment (SOFA) Score, Acute Physiology and Chronic Health Evaluation (APACHE) II score, Lung Injury Score (LIS), the Multi-Organ Dysfunction (MODS) score, Oxygenation index were missed.